Pink or white? asthma inhaler color may influence symptom perception
NCT ID NCT04886999
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the color of an asthma inhaler (pink vs white) affects how people perceive their asthma symptoms. 78 adults with moderate to severe asthma used both colored inhalers and reported their symptoms daily. The goal was to see if the device color alone could change symptom awareness or treatment satisfaction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
78 people
The number who actually took part.
- Started
-
Feb 2022
- Finished
-
Feb 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject's and/or subject legal representative's written informed consent obtained prior to any study related procedure. * Age: ≥18 and ≤75 years of age. * Established diagnosis of permanent asthma for at least 6 months prior to screening/randomisation visit * Subject on maintenance therapy treated by Foster® (CHF1535 100/6 µg pMDI) for at least 6 months prior to screening/randomisation visit * Asthma Control Test (ACT) ≥ 20 at screening/randomisation visit. * Subject must have a cooperative attitude and the ability to be trained to use correctly the diary and answer the Visual Analogue Scale (VAS) * Subject willing and able to download the application on their personal electronic device to fill in the study e-diary. * Female subject of non-childbearing potential defined as physiologically incapable of becoming pregnant or female subject + male Partner must be willing to use a highly effective birth control method from the signature of the informed consent and until Visit 4 Exclusion Criteria: * Pregnant or lactating woman * History of 'at risk' asthma * Recent exacerbation * Non-permanent asthma * Asthma requiring more than 1 inhaler for maintenance treatment and more than 1 inhaler for reliever treatment. * Asthma requiring use of biologics * Respiratory disorders * Lower tract respiratory infection * Current smoker or ex-smoker with a smoking current use/history of ≥ 10 pack-years * Cardiovascular diseases * Subject with historical or current evidence of uncontrolled concurrent disease such as but not limited to hyperthyroidism, diabetes mellitus or other endocrine disease, haematological disease and autoimmune disorders * Alcohol/drug abuse * Participation in an investigational trial within the last 30 days (60 days for biologics) or a more appropriate time as determined by the Investigator * Contra-indications to Foster® constituted an exclusion criterion * History of hypersensitivity to Foster® or any of its components or a history of any other allergy that in the opinion of the Investigator contra-indicated the subject's participation * Subject mentally or legally incapacitated or subject accommodated in an establishment as a result of an official or judicial order * Blind, colour-blind subject or any other dyschromatopsia * Known psychiatric disorders that may have interfered with successful completion of this protocol according to the Investigator's judgment including schizophrenia, bipolar disorders and psychoses.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chiesi Clinical Trial Site 38001
Milan, Italy
-
Chiesi Clinical Trial Site 38002
Roma, Italy
-
Chiesi Clinical Trial Site 38003
Genova, Italy
-
Chiesi Clinical Trial Site 38004
Palermo, Italy
-
Chiesi Clinical Trial Site 38005
Naples, Italy
-
Chiesi Clinical Trial Site 38006
Cagliari, Italy
-
Chiesi Clinical Trial Site 38007
Sassari, Italy
-
Chiesi Clinical Trial Site 38009
Battipaglia, Italy
-
Chiesi Clinical Trial Site 38010
Catanzaro, Italy
-
Chiesi Clinical Trial Site 38011
Bari, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Asthma's hidden switch: scientists hunt for calcium channels in Kids' immune cells
- Can a simple breath test cut asthma Flare-Ups?
- Breathing tests face off: can extra lung measurements improve asthma diagnosis?
- The carbon label on your inhaler: can it sway a Doctor's choice?
- Six biologics put to the test in Real-World asthma and COPD care
- Can a digital program help teens with chronic illnesses move to adult care?